A partial recombinant protein from the N-terminal region of human Luteinizing hormone / Choriogonadotropin receptor was used as the immunogen for the LHR antibody.
LHCGR
Reactivity: Rat
WB, ELISA
Host: Rabbit
Polyclonal
unconjugated
Application Notes
Optimal dilution of the LHR antibody should be determined by the researcher.\. FACS: 0.5-1 μg/million cells in 0.1ml,IF: 1-2 μg/mL,IHC (FFPE): 0.5-1 μg/mL for 30 min at RT
Restrictions
For Research Use only
Concentration
1 mg/mL
Buffer
1 mg/mL in 1X PBS, BSA free, sodium azide free
Preservative
Azide free
Storage
4 °C,-20 °C
Storage Comment
Store the LHR antibody at 2-8°C (with azide) or aliquot and store at -20°C or colder (without azide).
Recognizes a protein of 78-85 kDa, which is identified as the receptor for Luteinizing hormone / Choriogonadotropin (LHR/CGR). Luteinizing hormone plays a role in spermatogenesis and ovulation by stimulating the testes and ovaries to produce steroids. Choriogonadotropin production in the placenta maintains estrogen and progesterone levels during the first trimester of pregnancy. Ovaries and testes abundantly express luteinizing hormone / choriogonadotropin receptor (LHCGR) as a seven transmembrane, G protein-coupled receptor glycoprotein. LHCGR influences the protective effect of pregnancy and Gonadotropin against breast cancer. The expression of LHCGR on breast carcinoma correlates in part to the degree of tumor differentiation. LHCGR -positive breast tumors occur more frequently in tumors with greater cell differentiation in premenopausal women.